Rajiv Agarwal

Rajiv Agarwal practices at Vanderbilt University Medical Center in Nashville, Tennessee, part of Vanderbilt University Medical Center.

Rajiv Agarwal's NPI, 1790027936, was assigned on March 26, 2013. Rajiv Agarwal graduated from University of Chicago, Pritzker School of Medicine in 2013. Rajiv Agarwal holds Tennessee license 59069.

Rajiv Agarwal's primary practice is Vanderbilt University Medical Center, at 1211 Medical Center Drive, Nashville, TN 37232 in Davidson County. The practice phone is (615) 322-3454.

Rajiv Agarwal's primary practice is Vanderbilt University Medical Center in Nashville, Tennessee, part of Vanderbilt University Medical Center. The medical group on file is Vanderbilt University Medical Center. Dmand AI also links Rajiv Agarwal to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Rajiv Agarwal practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Rajiv Agarwal's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Rajiv Agarwal is licensed in Tennessee.

CMS data shows 520 Medicare services from Rajiv Agarwal across 7 procedure codes in 2024, for 128 Medicare patients. Medicare paid $33,818 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 128 Medicare patients who saw Rajiv Agarwal in 2024. The largest group is 65 to 74, with 67 patients. 75% of them have high blood pressure, and 67% have high cholesterol. Their average risk score is 2.63, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Rajiv Agarwal's median patient age at 74, with 54% women.

In 2024, Rajiv Agarwal wrote 557 Medicare Part D claims for 73 patients. 82% of them were for generic drugs. CMS names the drug for 316 of them, across 15 drugs with 11 or more claims each, at $87,226 in total drug cost. In 2023, CMS named 267 claims across 13 drugs.

Rajiv Agarwal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Rajiv Agarwal as offering telehealth.

Dmand AI links 375 papers to Rajiv Agarwal, published from 2002 to 2025. 2022 was the busiest year, with 25. The most frequent topics are Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2 and Hypertension. Rajiv Agarwal has published most often in Am J Nephrol. Rajiv Agarwal's most frequent co-authors are Rajiv Agarwal, MD, Bertram Pitt, MD and Arjun Daniel Sinha, MD.

Dmand AI links Rajiv Agarwal to 3 clinical trials, 2 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Renal Insufficiency, Chronic, Colonic Neoplasms and Colorectal Neoplasms.

CMS Open Payments shows 17 general payments to Rajiv Agarwal from 5 drug and device companies from 2020 to 2025. Food and beverage make up the largest share, 50% of the total. AstraZeneca Pharmaceuticals LP paid the most, $265.

Rajiv Agarwal graduated from University of Chicago, Pritzker School of Medicine in 2013.